NCT06801353View on ClinicalTrials.gov

A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

December 1, 2025

Study Completion Date

July 1, 2026

Conditions
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)Biological TherapyBiomarkers
Interventions
BIOLOGICAL

Stapokibart

Stapokibart subcutaneously every two weeks

DRUG

Mometasone Furoate Nasal Spray (MFNS)

mometasone furoate nasal spray 200 μg once daily

Trial Locations (1)

100000

Beijing Tongren Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Tongren Hospital

OTHER